Arcus Biosciences [RCUS] vs Bio-Techne [TECH] Detailed Stock Comparison

Arcus Biosciences Inc.

NYSE
Loading...

Bio-Techne Corporation

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Arcus Biosciences Inc. wins in 2 metrics, Bio-Techne Corporation wins in 15 metrics, with 0 ties. Bio-Techne Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Arcus Biosciences Inc. Bio-Techne Corporation Better
P/E Ratio (TTM) N/A 117.16 N/A
Price-to-Book Ratio 4.99 4.55 Bio-Techne Corporation
Debt-to-Equity Ratio 34.71 20.07 Bio-Techne Corporation
PEG Ratio -7.12 -0.82 Bio-Techne Corporation
EV/EBITDA -6.35 28.87 Bio-Techne Corporation
Profit Margin (TTM) -142.92% 6.41% Bio-Techne Corporation
Operating Margin (TTM) -345.45% 14.51% Bio-Techne Corporation
EBITDA Margin (TTM) N/A 14.51% N/A
Return on Equity -63.26% 3.80% Bio-Techne Corporation
Return on Assets (TTM) -21.08% 6.09% Bio-Techne Corporation
Free Cash Flow (TTM) $-484.00M $256.55M Bio-Techne Corporation
Dividend Yield N/A 0.62% N/A
1-Year Return 183.76% 6.78% Arcus Biosciences Inc.
Price-to-Sales Ratio (TTM) 12.78 7.35 Bio-Techne Corporation
Enterprise Value $2.39B $9.19B Bio-Techne Corporation
EV/Revenue Ratio 9.67 7.56 Bio-Techne Corporation
Gross Profit Margin (TTM) N/A 62.72% N/A
Revenue per Share (TTM) $2 $8 Bio-Techne Corporation
Earnings per Share (Diluted) $-3.29 $0.49 Bio-Techne Corporation
Beta (Stock Volatility) 0.86 1.47 Arcus Biosciences Inc.
Short % of Float 11.16% 5.09% Bio-Techne Corporation

Arcus Biosciences Inc. vs Bio-Techne Corporation Stock Performance Analysis

Loading Price Chart...

RCUS
TECH

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Arcus Biosciences Inc.-2.49%-0.46%-8.41%6.38%-6.91%2.45%
Bio-Techne Corporation2.17%5.74%-7.11%-10.77%-20.32%-14.75%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Arcus Biosciences Inc.183.76%20.61%1.16%43.98%43.98%43.98%
Bio-Techne Corporation6.78%-37.73%-51.28%86.91%161.27%281.12%

Performance & Financial Health Analysis: Arcus Biosciences Inc. vs Bio-Techne Corporation

MetricRCUSTECH
Market Information
Market Cap i$3.20B$9.07B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,560,5832,151,790
90 Day Avg. Volume i1,285,6912,370,067
Last Close$23.86$50.85
52 Week Range$7.91 - $28.72$43.20 - $72.16
% from 52W High-16.92%-29.53%
All-Time High$49.10 (Nov 22, 2021)$135.96 (Sep 20, 2021)
% from All-Time High-51.41%-62.60%
Growth Metrics
Quarterly Revenue Growth0.27%-0.01%
Quarterly Earnings Growth0.27%0.14%
Financial Health
Profit Margin (TTM) i-1.43%0.06%
Operating Margin (TTM) i-3.45%0.15%
Return on Equity (TTM) i-0.63%0.04%
Debt to Equity (MRQ) i34.7120.07
Cash & Liquidity
Book Value per Share (MRQ)$5.04$12.62
Cash per Share (MRQ)$7.83$0.93
Operating Cash Flow (TTM) i$-482,000,000$251.25M
Levered Free Cash Flow (TTM) i$-162,250,000$274.30M
Dividends
Last 12-Month Dividend Yield iN/A0.62%
Last 12-Month Dividend iN/A$0.40

Valuation & Enterprise Metrics Analysis: Arcus Biosciences Inc. vs Bio-Techne Corporation

MetricRCUS (Apr 26, 2026)TECH (Nov 10, 2025)
Price Ratios
P/E Ratio (TTM) iN/A117.16
Forward P/E i-7.1226.21
PEG Ratio i-7.12-0.82
Price to Sales (TTM) i12.787.35
Price to Book (MRQ) i4.994.55
Market Capitalization
Market Capitalization i$3.20B$9.07B
Enterprise Value i$2.39B$9.19B
Enterprise Value Metrics
Enterprise to Revenue i9.677.56
Enterprise to EBITDA i-6.3528.87
Risk & Other Metrics
Beta i0.861.47
Book Value per Share (MRQ) i$5.04$12.62

Financial Statements Comparison: Arcus Biosciences Inc. vs Bio-Techne Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRCUS (2025)TECH (2025)
Revenue/Sales i247.00M1.22B
Cost of Goods Sold iN/A429.36M
COGS % of Revenue i0.0%35.2%
Gross Profit iN/A790.27M
Gross Margin i0.0%64.8%
Research & Development i523.00M99.50M
Operating Income (EBIT) i-386.00M242.80M
Operating Margin i-156.3%19.9%
EBITDA i-335.00M357.57M
EBITDA Margin i-135.6%29.3%
Pre-Tax Income i-353.00M98.46M
Pre-Tax Income % of Revenue i-142.9%8.1%
Income Tax i025.06M
Income Tax % of Revenue i0.0%2.1%
Net Income (Profit) i-353.00M73.40M
Profit Margin i-142.9%6.0%

Balance Sheet & Liquidity Metrics

MetricRCUS (2025)TECH (2025)
Cash & Equivalents i222.00M162.19M
Total Current Assets i1.01B608.30M
Total Current Assets % of Revenue i407.7%49.9%
Total Current Liabilities i231.00M175.85M
Total Current Liabilities % of Revenue i93.5%14.4%
Long-Term Debt i99.00M429.96M
Long-Term Debt % of Revenue i40.1%35.3%
Total Shareholders Equity i631.00M1.92B
Retained Earnings i-1.49B1.07B
Retained Earnings % of Revenue i-601.2%87.4%
Property, Plant & Equipment i28.00M73.40M

Cash Flow Statement Comparison

MetricRCUS (2025)TECH (2025)
Operating Cash Flow i-469.00M185.64M
Operating Cash Flow % of Revenue i-189.9%15.2%
Capital Expenditures i-2.00M-31.01M
Free Cash Flow i-484.00M256.55M
FCF Margin i-196.0%21.0%
Debt Repayment iN/A-77.00M
Common Stock Repurchase iN/A-275.73M

Short Interest & Institutional Ownership Analysis

MetricRCUSTECH
Shares Short i9.88M6.94M
Short Ratio i7.592.59
Short % of Float i11.16%5.09%
Shares Outstanding i125.30M154.97M
Float Shares i88.65M153.94M
% Held by Insiders i29.17%0.28%
% Held by Institutions i74.41%102.89%
% Held by Public i-3.58%-3.17%

Dividend Analysis & Yield Comparison: Arcus Biosciences Inc. vs Bio-Techne Corporation

MetricRCUSTECH
Last 12-Month Dividend iN/A$0.40
Last 12-Month Dividend Yield iN/A0.62%
3-Year Avg Annual Dividend iN/A$0.32
3-Year Avg Dividend Yield iN/A0.12%
3-Year Total Dividends iN/A$0.96
Ex-Dividend DateN/AFeb 13, 2026